Your browser version may not work well with NCBI's Web applications. More information here...
1: Microbes Infect. 2005 Nov;7(14):1392-9. Epub 2005 Sep 15.
Related Articles, Links
Click here to read
Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env.

Ensoli B, Cafaro A, Caputo A, Fiorelli V, Ensoli F, Gavioli R, Ferrantelli F, Cara A, Titti F, Magnani M.

AIDS National Center, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Roma, Italy. ensoli@iss.it

The promising results obtained with the HIV-1 Tat-based vaccines in mice, monkeys and humans, a better understanding of Tat immunomodulatory functions, as well as evidence that vaccination with trimeric V2 loop-deleted HIV-1 Env induces cross-clade neutralizing antibodies led to the rational design of a novel vaccine based on the combination of Tat and V2-deleted Env.

PMID: 16243561 [PubMed - indexed for MEDLINE]